HPV Vaccine May Cut Men's Cancer Risk by 46%

A groundbreaking study has revealed that the HPV vaccine may significantly reduce men's risk of developing several types of cancer, including those affecting the mouth, throat, and penis. Researchers analyzed health records from over three million young men and found that those who received the nine-strain version of the vaccine had a 46% lower risk of HPV-related cancers compared to unvaccinated peers. This finding challenges long-held assumptions that the vaccine's benefits are primarily limited to women, particularly in preventing cervical cancer. The study, published in *JAMA Oncology*, offers some of the clearest evidence yet that the vaccine can protect men from a range of malignancies linked to human papillomavirus (HPV).

The study's implications extend beyond statistics. For every 100,000 unvaccinated males, approximately 12.5 cases of HPV-related cancer were recorded annually. Among vaccinated males, that number dropped to 7.8 per 100,000. This protective effect was consistent across both teenage boys and young adults, suggesting the vaccine's efficacy spans a broad age range. HPV, which spreads through skin-to-skin contact, is a common virus, but its role in causing cancer has long been underappreciated in men. While cervical cancer in women has dominated public health discussions, cancers of the head, neck, and genitals in men have remained in the shadows.

Until now, most evidence supporting the HPV vaccine's cancer-preventive power focused on women. Earlier studies in men often measured infection rates rather than cancer outcomes, leaving gaps in understanding the vaccine's true impact. This new research directly compared vaccinated and unvaccinated males, offering a more robust analysis. Scientists argue that expanding vaccination programs to include boys could reduce HPV transmission globally, protect men directly, and accelerate the decline of HPV-related cancers. Yet, many countries still prioritize girls for vaccination, a policy that some experts say may be outdated.

The UK has taken a step forward by extending its HPV vaccination program to all boys in Year 8 (aged 12 to 13) since 2019. This shift ensures broader protection against cancers linked to high-risk HPV strains. The vaccine is typically administered through school-based programs, targeting strains associated with cervical, genital, and head-and-neck cancers. Additionally, men who have sex with men up to age 45 can access the vaccine for free at sexual health clinics, a measure aimed at addressing higher anal cancer risks in this group.

Despite these advancements, researchers caution that HPV-related cancers in young men remain rare, and not all cancers studied are caused by the virus. Longer-term follow-up over decades will be necessary to fully assess the vaccine's impact. However, the findings underscore a critical message: the HPV vaccine is not just for girls. It could play a pivotal role in preventing cancer in men, particularly as oral sex—linked to oropharyngeal cancer—is a leading risk factor. While most people clear HPV infections naturally, persistent infections can lead to cancer over time.

If the vaccine's benefits for men are as significant as this study suggests, why do many nations still lag in including boys in their programs? Could broader vaccination efforts save countless lives while reducing the global burden of HPV-related cancers? The answer may lie not only in science but in the willingness of public health systems to adapt and prioritize equitable protection for all genders.